COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01274494
First received: January 10, 2011
Last updated: September 10, 2013
Last verified: September 2013

January 10, 2011
September 10, 2013
May 2011
September 2012   (final data collection date for primary outcome measure)
Compliance rate [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Identify the percentage of subjects compliant to their antihypertensive treatment.
  • Identify the number and percentage of subjects adequately controlling their high blood pressure according to the JNC VII criteria. [ Time Frame: Visit 1 ] [ Designated as safety issue: No ]
    Identify the number and percentage of subjects adequately controlling their high blood pressure according to the JNC VII criteria.
  • Identify the number and percentage of subjects adequately controlling their high blood pressure according to the JNC VII criteria. [ Time Frame: Visit 2 ] [ Designated as safety issue: No ]
    Identify the number and percentage of subjects adequately controlling their high blood pressure according to the JNC VII criteria.
  • Identify the number and percentage of subjects adequately controlling their high blood pressure according to the JNC VII criteria. [ Time Frame: Visit 3 ] [ Designated as safety issue: No ]
    Identify the number and percentage of subjects adequately controlling their high blood pressure according to the JNC VII criteria.
Complete list of historical versions of study NCT01274494 on ClinicalTrials.gov Archive Site
  • Health Related Quality of Life (MINICHAL Score) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To compare and identify changes in the quality of life before and after anti-hypertensive treatment.
  • Type of pharmacological treatments [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To identify the pharmacological treatments used by physicians in Jordan and Lebanon to treat patients newly diagnosed or with uncontrolled hypertension.
  • Factors affecting adherence to treatment [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To identify associated factors that may alter adherence to anti-hypertensive treatment.
  • Compliance rate by antihypertensive regimen used [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To compare treatment rate for different antihypertensive regimen used
  • Percentage of controlled patients [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    To identify the percentage of patients reaching their target blood pressure according to the JNCVII criteria.
  • To compare and identify changes in the quality of life before and after anti-hypertensive treatment. [ Time Frame: Visit 1 ] [ Designated as safety issue: No ]
    To compare and identify changes in the quality of life before and after anti-hypertensive treatment.
  • To compare and identify changes in the quality of life before and after anti-hypertensive treatment. [ Time Frame: Visit 2 ] [ Designated as safety issue: No ]
    To compare and identify changes in the quality of life before and after anti-hypertensive treatment.
  • To compare and identify changes in the quality of life before and after anti-hypertensive treatment. [ Time Frame: Visit 3 ] [ Designated as safety issue: No ]
    To compare and identify changes in the quality of life before and after anti-hypertensive treatment.
  • To identify the pharmacological treatments and practice used my physicians in Jordan and Lebanon to treat patients newly diagnosed or with uncontrolled hypertension. [ Time Frame: Visit 1 ] [ Designated as safety issue: No ]
    To identify the pharmacological treatments and practice used my physicians in Jordan and Lebanon to treat patients newly diagnosed or with uncontrolled hypertension.
  • To identify the pharmacological treatments and practice used my physicians in Jordan and Lebanon to treat patients newly diagnosed or with uncontrolled hypertension. [ Time Frame: Visit 2 ] [ Designated as safety issue: No ]
    To identify the pharmacological treatments and practice used my physicians in Jordan and Lebanon to treat patients newly diagnosed or with uncontrolled hypertension.
  • To identify the pharmacological treatments and practice used my physicians in Jordan and Lebanon to treat patients newly diagnosed or with uncontrolled hypertension. [ Time Frame: Visit 3 ] [ Designated as safety issue: No ]
    To identify the pharmacological treatments and practice used my physicians in Jordan and Lebanon to treat patients newly diagnosed or with uncontrolled hypertension.
Not Provided
Not Provided
 
COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication
COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication

The aim of this multi-centre survey is to assess treatment adherence and quality of life in a Jordanian and Lebanese population newly diagnosed with hypertension or with uncontrolled essential hypertension being on antihypertensive treatment for at least 6 months.

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

multi-centre survey of patients

High Blood Pressure
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1501
September 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients older than 21 years of age
  • Patients newly diagnosis with essential hypertension or with hypertension that is uncontrolled after being under the same antihypertensive treatment for at least 6 months (based on the criteria established by the Joint National Committee VII)
  • Patients capable of providing an informed consent

Exclusion Criteria:

  • Patients with secondary hypertension
  • Pregnant women or nursing mothers
  • Patients with acute illnesses or psychiatric diagnosis
Both
21 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01274494
NIS-CME-ATA-2010/1
No
AstraZeneca
AstraZeneca
Not Provided
Not Provided
AstraZeneca
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP